To validate if some degree of GLO1 inhibition is present in tumor tissue, we assessed levels of sLG, the direct GLO1 product, and accordingly observed a trend of reduced levels of sLG in tumors (N = 70; Fig. 4A), further indicating potentially lower activity/lower flux through the GLO1 enzyme in our patient cohort. The gene discussed is SIGLEC12; the disease is neoplasm.